EUVIMEDEUVIMED entdecken
Open Access

Commercial markups on pediatric oncology drugs at 340B pediatric hospitals

Ian T T Liu iD, Junyi Wang, Ameet Sarpatwari, Aaron S Kesselheim, William B Feldman iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Ian T T Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Hospitals, Pediatric, Antineoplastic Agents, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Arnold Ventures, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eligible pediatric hospitals can purchase clinician‐administered drugs at discounted rates through the 340B Drug Pricing Program and charge payers prices exceeding drug acquisition costs, but the magnitude of these markups is not known. In a study of newly approved oncology drugs at pediatric 340B hospitals, median negotiated prices ranged from 102% (interquartile range [IQR]: 91%–156%) of average sales price (ASP) at Phoenix Children's Hospital to 630% (IQR: 526%–630%) at Driscoll Children's Hospital. Pediatric hospitals participating in the federal 340B Drug Pricing Program can extract steep payments on new drugs from commercial insurers, though with wide variation between and within hospitals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hospitals, PediatricAntineoplastic AgentsDrug CostsHumansChildUnited StatesNeoplasms

Stichwörter der Autor:innen

340Bdrug pricingpediatric oncology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Ian T T Liu, William B Feldman

Förderung

  • NHLBI NIH HHS
  • Arnold Ventures
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Liu, I. T. T., Wang, J., Sarpatwari, A., Kesselheim, A. S., & Feldman, W. B. (2024). Commercial markups on pediatric oncology drugs at 340B pediatric hospitals. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31158

Vancouver

Liu ITT, Wang J, Sarpatwari A, Kesselheim AS, Feldman WB. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31158

BibTeX
@article{Liu2024,
  author = {Liu, Ian T T and Wang, Junyi and Sarpatwari, Ameet and Kesselheim, Aaron S and Feldman, William B},
  title = {Commercial markups on pediatric oncology drugs at 340B pediatric hospitals},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31158}
}
Kostenlos starten →